TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Orig3n Stock

Orig3n Stock

orig3n.comHealthcare / BioTech & PharmaFounded: 2014Funding to Date: $85.64MM

Orig3n is a developer of DNA tests designed to help people understand the links between their genes and how their minds and bodies work, and researcher of cellular science to develop personalized therapies for repairing tissue damage and disease.

Buy or sell Orig3n stockLearn more about Orig3n IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Orig3n, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Orig3n’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Orig3n.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Robin Smith
Co-Founder & Chief Executive Officer
Marcie Glicksman Ph.D
Chief Scientific Officer
Kate Blanchard
Co-Founder & Chief Operating Officer
Michael Fang MD
Chief Medical Officer

Board Members

Justin Xiang Ph.D
Syno Capital
Byron Smith
Mountain Group Partners
Angela Ruggiero

Frequently Asked Questions About Orig3n’s Stock

plusminus
Can you buy Orig3n’s stock?
Orig3n is not publicly traded on NYSE or NASDAQ in the U.S. To buy Orig3n’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Orig3n’s stock?
Yes, you can sell stock of a private company like Orig3n. Forge can help you sell your Orig3n stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Orig3n’s stock price?
Orig3n is a privately held company and therefore does not have a public stock price. However, you may access Orig3n’s private market stock price with Forge Data.
plusminus
What is Orig3n’s stock ticker symbol?
Orig3n does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Orig3n in the BioTech & Pharma sector

Egenesis

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$387.57MM

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Prime Medicine

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.23B

ADARx Pharmaceuticals

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

Pendulum Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM

Cytonics

Sector
Healthcare / BioTech & Pharma
 
 

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

News Highlights

Boston Globe 09/08/2020
State suspends COVID-19 testing at Orig3n, Boston lab responsible for at least 383 false positive results - The Boston Globe
A state investigation found the lab “put patients at immediate risk of harm.”

Trending Companies

Frequently Asked Questions

Updated on: Apr 24, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.